IDD 3

Drug Profile

IDD 3

Alternative Names: IDD-3; Melanoma vaccine - IDM Pharma; Uvidem

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDM Pharma
  • Developer Takeda America Holdings
  • Class Antineoplastics; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
  • 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
  • 06 Nov 2007 Updated results from a phase II clinical trial (DC-MEL-202) in patients with advanced melanoma added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top